A Harvard economist just measured something nobody could pin down before: exactly how much America penalizes people for being overweight — and what happens the moment that weight disappears.
The tool that made it possible?
GLP-1 drugs.
Ozempic, Wegovy, and their cousins have quietly become a mass experiment in real time.
22% of American women.
14% of American men.
That's how many have already taken these drugs — for weight loss, diabetes, or both.
Millions of people, shedding pounds fast, all at once.
Rebecca Diamond of Harvard saw an opportunity economists rarely get.
For years, research has quietly shown something uncomfortable.
People carrying extra weight — especially women — tend to:
Not because of ability. Because of first impressions.
Diamond wanted to know: if you strip the weight away, does the penalty disappear too?
Using the Understanding America Study — 15,000 people tracked over years — Diamond compared women starting GLP-1s against women who wanted to start but hadn't yet.
Same desire to lose weight. Different starting point in time.
Then she watched what happened next:
Almost 30 points.
On both fronts.
This isn't just a health story.
It's proof that a huge chunk of the "penalty" obese people pay isn't about health, energy, or performance.
It's about the split-second judgment a stranger makes — a hiring manager, a date, a landlord.
Change the body fast enough, and those snap judgments flip before anyone gets to know the real person underneath.
If a drug can erase decades of social and economic bias in eighteen months…
what does that say about the bias itself.
That's all for now!
